RESEARCH TRIANGLE PARK, N.C., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Locus Biosciences, Inc. (“Locus”), a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage ...
MOUNTAIN VIEW, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Locus Technologies, the sustainability and Environmental Health and Safety (EHS) compliance software leader, announced the release of Locus ...
TAIPEI, Sept. 29, 2025 /PRNewswire/ -- Locus Cell (TWSE: 6891), a leading regenerative medicine CDMO in Taiwan, announced it has signed a Memorandum of Understanding (MOU) with Australia-based Cambium ...
Locus Biosciences (Locus) has begun treating the first patient in its phase 2/3 trial of LBP-EC01, in partnership with the Biomedical Advanced Research and Development Authority (BARDA), for the ...
RESEARCH TRIANGLE PARK – Morrisville-based Locus Biosciences, a developer of precision antibacterial therapies, will conduct the world’s first clinical trial of a recombinant bacteriophage therapy, a ...
Locus Technologies has announced a new iPhone application for field data collection. eWell for the iPhone consists of two linked components: the iPhone application itself, and Locus' Environmental ...
, Thirty-Eight in downtown Grand Rapids is a perfect fit. Locus Development signed the Cascade-based Adtegrity.com as the first tenant for its mixed-use project at the corner of Weston and Commerce.
Locus Pharmaceuticals Completes $30.2 Million Financing Round Locus Pharmaceuticals, Inc., a computationally based drug design and development company, announced today that it has closed on a $30.2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback